Uncategorized
VIDEO: Rho kinase inhibitors beneficial as adjunctive glaucoma therapy
NEW YORK ― At the American Glaucoma Society annual meeting, Savak "Sev" Teymoorian, MD, MBA discusses the benefits of Rho-kinase inhibitors as adjunctive glaucoma therapy. Compared with prostaglandin, Rho kinase inhibitors need only once-daily treatment and are associated with no systemic side effects.